X
[{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL\u2122 to Phase I Clinical Trial for Alzheimer's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuro-inflammation Biotech Jupiter Neurosciences Revises Terms Ahead Of $15 million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for PREVENTION 8 (RESVERATROL)
Filters
Companies By Therapeutic Area
Details:
Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.
Lead Product(s):
Resveratrol
Therapeutic Area: Genetic Disease
Product Name: Jotrol
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Spartan Capital Securities
Deal Size: $15.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
December 02, 2022
Details:
The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.
Lead Product(s):
Resveratrol
Therapeutic Area: Neurology
Product Name: Jotrol
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 01, 2020
Details:
The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Lead Product(s):
Resveratrol
Therapeutic Area: Neurology
Product Name: Jotrol
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $1.7 million
Upfront Cash: Undisclosed
Deal Type: Funding
September 22, 2020